Press coverage about Voyager Therapeutics (NASDAQ:VYGR) has been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Voyager Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.2493602404531 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Stocks Showing Rising Market Leadership: Voyager Therapeutics Earns 83 RS Rating (finance.yahoo.com)
- Voyager Therapeutics (VYGR) Research Coverage Started at BTIG Research (americanbankingnews.com)
- Voyager Therapeutics, Inc. (VYGR) in Noticeable for Active Investors on Short/Long-Term obligations – Stock News Stop (stockmarketstop.com)
- -$0.74 Earnings Per Share Expected for Voyager Therapeutics Inc (VYGR) This Quarter (americanbankingnews.com)
A number of research analysts recently weighed in on the stock. ValuEngine upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. BTIG Research assumed coverage on shares of Voyager Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $32.00 price objective on the stock. Chardan Capital restated a “hold” rating and set a $17.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Wedbush restated a “positive” rating and set a $31.00 price objective (down previously from $36.00) on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $28.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, November 28th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $26.90.
In other Voyager Therapeutics news, insider Bernard Ravina sold 5,490 shares of the stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $13.63, for a total value of $74,828.70. Following the transaction, the insider now directly owns 10,983 shares in the company, valued at $149,698.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 21,960 shares of company stock worth $370,850 over the last quarter. Insiders own 8.00% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.